MaxWell Webinar with Dr. Matt Kelley

Due to confidentiality reasons, we are unable to provide a recording of the webinar at this time. Stay tuned for future webinars, and make sure not to miss them!

This webinar covered:

HD-MEA use cases in drug discovery research featuring ex-vivo and in-vitro preparations.

A human model of Dravet syndrome, using patient-derived iPSC neurons characterized by HD-MEAs.

High-throughput spike sorting analysis to assess neuronal responses to ion channel potentiators.

Speaker

Dr. Matt Kelley
Alexion-AstraZeneca Rare Disease
USA

Host

Dr. Laura D’Ignazio
MaxWell Biosystems
Switzerland

Title

Progressing Neuroscience Drug Discovery Through HD-MEAs

Abstract

High-density microelectrode arrays (HD-MEAs) are a powerful, emerging technology in neuroscience drug discovery. These arrays enable simultaneous, non-invasive, real-time monitoring of electrical activity from neurons at scale, offering a detailed perspective on network dynamics and individual neuron functionality, including axon physiology. We will discuss various use cases of HD-MEAs in drug discovery research featuring ex-vivo and in-vitro preparations. The presentation will include the introduction of a human model of Dravet syndrome, developed using patient induced pluripotent stem cell (iPSC) derived neurons and characterized by HD-MEAs. We will discuss how our spike sorting analysis pipeline enables high throughput assessment of neuronal response to an ion channel potentiator. The primary aim of this presentation is to explore the current applications and next steps of HD-MEA technology in the realm of drug discovery research, emphasizing its potential to bring value to the development of novel treatments for patients with neurological disease.

Speaker Bio

Matthew Kelley is a Senior Scientist at Alexion – AstraZeneca Rare Disease focused on discovery and development of drugs for rare neurological diseases. Prior to AstraZeneca, Matt held neuroscience research positions at Pfizer and Amgen using high-density microelectrode array (HD-MEA) technology. At Pfizer, Matt led gene therapy and small molecule discovery programs. Matt has also performed discovery research in neuroscience gene therapy at Voyager Therapeutics. He earned his PhD in neuroscience from Tufts University and his B.S.in neuroscience from UCLA.